clinical trial · NCT06372457
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol-Myers Squibb·—·active not recruiting·n = 331
Hypertrophic Cardiomyopathy (HCM)Approved Hypertrophic Cardiomyopathy drug treatmentsMavacamten
brief summary
COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.
started
Dec 1, 2023
primary completion
Sep 29, 2025
completion
Jun 30, 2026
last updated
May 4, 2026
detailed description
The mavaCamten ObservationaL evIdence Global cOnsortium in hypertrophic cardiomyopathy (COLLIGO-HCM) is a global observational research initiative aiming to describe the real-world outcomes of treatments for obstructive hypertrophic cardiomyopathy (HCM), including mavacamten.
This retrospective study uses data from existing medical records and electronic registries from HCM centers around the world.
official title
mavaCamten ObservationaL evIdence Global cOnsortium in HCM (COLLIGO-HCM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol